An interventional study of Chlorhexidine gluconate impregnated bordered polyurethane dressing and Standard bordered polyurethane dressing in Vascular Access Complication, Device Related Infection and Device Related Sepsis, sponsored by The University of Queensland. Completed at 3 sites in 2 countries. Open to participants aged 6 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by The University of Queensland · Not applicable, Interventional, and Prevention
The goal of this clinical trial is to compare a chlorhexidine impregnated dressing for peripheral intravenous catheters (PIVCs) to the standard dressing currently used in general medical and surgical inpatient wards.
The main questions it aims to answer are:
Participants will be randomly allocated to receive either of the below dressings to cover and secure their PIVC:
Researchers will compare standard and CHG dressings to see if the presence of CHG improves the occurrence of infectious complications related to the PIVC.
This study is a multi-centre, two-arm, parallel group adaptive Randomized Controlled Trial (RCT) to test effectiveness, cost-effectiveness, and safety of 3M™ Tegaderm™ Antimicrobial IV Advanced Securement dressings with standard polyurethane dressings for PIVCs. The study has two phases. Phase I is an internal feasibility pilot for which only feasibility outcomes will be considered (no analysis). At this time (n=300) an independent Data Safety Monitoring Committee (DSMC) comprised of a biostatistician, physician and expert trialist will review pre-defined blinded analyses of feasibility and safety data. Phase II will then go ahead if feasibility outcomes are satisfactory, and will involve continuation of trial recruitment to complete a definitive RCT. If Phase II does not proceed then all outcomes will be reported at the end of Phase I.
Setting and sample:
Australia: The ProP Trial will be undertaken in the general medical/surgical and oncology/hematology departments at the Queensland Children's Hospital (QCH; Site 1), and the general medical/surgical departments at the Royal Brisbane and Women's Hospital (RBWH; Site 2) Brisbane, Australia. These are both large quaternary referral teaching hospitals (Site 1: 359 beds; Site 2: 929 beds).
France: The ProP Trial will be undertaken in the University Hospital of Poitiers (PUH), a large referral teaching hospital with 959 acute beds. Patients will be recruited at the Emergency Department, before being admitted to medical wards.
Sample size:
Phase 1: The investigators will recruit 300 patients (200 Australia and 100 France) with 150 patients per arm. This sample size is not determined by statistical power but to test protocol feasibility and gain estimates of effect to inform a sample size calculation for a full trial. The investigators aim to recruit 300 patients over 16 weeks (19 per week).
Phase 2: The investigators will continue recruitment to the sample size recommended by the DSMC and the Trial Steering Committee. The investigators anticipate this will be no more than a sample of 2624 patients (1312/group) which would have 90% power to detect an absolute 5% reduction in the primary outcome from 22% to 17% (2-way alpha 0.05) (http://powerandsamplesize.com/calculators).
35 studies on the registry are indexed under Prosthesis-Related Infections; 10 are open to participants now.
This study's enrollment of 300 is above the median of 193 across 20 interventional studies indexed under Prosthesis-Related Infections.
Browse Prosthesis-Related Infections studies →The University of Queensland is the lead sponsor of 91 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Australia only
France only
Exclusion Criteria:
Additional exclusions to Australian study only
Additional exclusions to French study only
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bordered Polyurethane Dressing
Device: Standard bordered polyurethane dressing
CHG Bordered Polyurethane Dressing
Device: Chlorhexidine gluconate impregnated bordered polyurethane dressing
PIVCs will be dressed and secured at the participating sites * RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing. * QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference.
Also known as: Tegaderm™ Antimicrobial I.V. Advanced Securement (9132)
PIVCs will be dressed and secured as per standard practice at the participating sites * RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing. * QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference.
Also known as: Tegaderm™ IV Advanced (1682 or 1683)
Feasibility for a definitive RCT
The feasibility of conducting a definitive RCT will be assessed against the following criteria: i. Study Eligibility as per inclusion/exclusion criteria (≥80% of screened participants will be eligible for study inclusion) ii. Participant Recruitment onto study (≥80% of eligible participants will provide informed consent to participate in the study) iii. Retention of study participants (\<10% will be lost to follow up) iv. Protocol fidelity of study participants (≥80% will receive the allocated intervention) v. Missing data for primary outcome 2 (\<5% of primary outcome 2 data will be unable to be collected) vi. Satisfaction of participants/parents and staff (\<10% report "low" satisfaction with the intervention arm (rated low/medium/high) vii. An estimate of catheter-related infectious complications (defined as per primary outcome 2) in the control group that indicate a fully powered multi-site RCT is achievable
Time frame: On completion of 300 participants
Catheter-related infectious complications and phlebitis
Proportion of patients with a composite measure of PIVC Colonization; PIVC local infection; PIVC-associated Bloodstream Infection (BSI) and Phlebitis. These measures are defined below in secondary outcomes. If patients meet more than one of the following \[e.g., phlebitis and PIVC local infection\], both will be collected however only counted once for the composite measure.
Time frame: Daily until 48hours after study PIVC is removed.
PIVC tip colonization
\>15 cfu of a pathogen semi-quantitative method, or ≥1000 cfu of a pathogen per mL broth method. PIVC tips will be collected based on Nurse and laboratory availability at time of PIVC removal.
Time frame: Daily until 48hours after study PIVC is removed.
PIVC local infection without Bloodstream Infection (BSI)
Proportion of patients with a PIVC local infection without BSI as defined by NHSN 2021 criteria for Cardiovascular System VASC-Arterial or Venous Infection (CVS-VASC); adult and child/infant criteria. Collected daily by either the research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record and microbiology results.
Time frame: Daily until 48hours after study PIVC is removed.
PIVC-associated Bloodstream Infection
Proportion of patients with a laboratory Confirmed Bloodstream Infection, as defined by NHSN 2021 adult and infant criteria Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record and microbiology results.
Time frame: Daily until 48hours after study PIVC is removed.
Phlebitis
Either pain or tenderness \[\>1 on a scale of 0 to 10\]), or at least 2 of erythema, swelling, purulence or palpable cord. Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Time frame: Daily until 48hours after study PIVC is removed.
PIVC device failure
Proportion of patients, a composite of infiltration/ extravasation, blockage/occlusion (with/without leakage), phlebitis (as defined above), thrombosis, dislodgement (complete/partial) or infection (as defined above). Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Time frame: Daily until 48hours after study PIVC is removed.
Dressing durability
Proportion of patients with dressing durability assessed as: (i) the dressing remains adhered to the skin on all four sides until PIVC removal; and, (ii) accidental dislodgement (excluding patients who deliberately remove their PIVC). Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Time frame: Daily until study PIVC is removed.
Skin colonization
Reported semi-quantitatively as scant, 1+, 2+, 3. PIVC skin swabs will be collected based on Nurse and laboratory availability at time of PIVC removal.
Time frame: On study PIVC removal
Adverse skin event
Proportion of patients with skin complications at PIVC site: mechanical (e.g. pressure injury, skin tears, blisters, bruising) or inflammatory complications (e.g. contact/allergic dermatitis, skin rash, pruritus). Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Time frame: Daily until 48hours after study PIVC is removed.
Serious adverse event
Proportion of patients with anaphylactic reaction to CHG in dressing; or mortality related to PIVC infection. Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Time frame: Daily until 48hours after study PIVC is removed.
Cost effectiveness
Direct and indirect healthcare costs to the health system, including cost per complication avoided. Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record and microbiology results. A random subset of 15% of participants will have all subsequent devices recorded until completion of treatment for the participant's current admission. Date of discharge will be recorded for all participants to calculate length of stay.
Time frame: Until discharge.
Patient reported experience measures of the dressing
Proportion of participants/parents who report their satisfaction with the dressing rated low/medium/high with respective prompts of: 1. "I'd rather use a different dressing next time" 2. "The dressing was ok, but I'm happy to try other types" 3. "It was a really good dressing and I'd like to use this one again" A Patient-Reported Experience Measure survey will be conducted on study PIVC removal. Patient's will have the opportunity to comment on the dressing and their satisfaction with it at any time during study participation.
Time frame: Daily until 48hours after study PIVC is removed.
Clinician reported experience measures of the dressing including application and removal
Proportion of clinicians who report their satisfaction with the dressing rated low/medium/high with respective prompts of: 1. "I'd rather use a different dressing next time" 2. "The dressing was ok, but I'm happy to try other types" 3. "It was a really good dressing and I'd like to use this one again" Collected opportunistically between dressing application to 48 hours after study PIVC removal.
Time frame: Daily until 48hours after study PIVC is removed.
Plan to share: Yes — Available to individuals who provide a methodologically sound proposal and at the discretion of the Principal Investigator.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prosthesis-Related Infections →
The University of Queensland